Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (241-250 of 435) with videos related to

Pageof 44
Sort By:
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Rheumatology and Therapy|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Rheumatology and Therapy|October 12, 2021
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1Vibeke Strand, Philip J Mease, Enrique R Soriano, et al.
The Journal of Rheumatology|August 4, 2005
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritisJoachim R Kalden, Christian Antoni, Jose M Alvaro-Gracia, et al.
The Journal of Rheumatology|September 3, 2011
Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experienceCharles G Peterfy, Peter Countryman, Annarita Gabriele, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
Rheumatology (Oxford, England)|December 14, 2020
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPYVibeke Strand, Namita Tundia, Alvin Wells, et al.
The Journal of Rheumatology|March 3, 2015
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working GroupDinesh Khanna, Shikha Mittoo, Rohit Aggarwal, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|October 27, 2017
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic StudyChristine Ballegaard, Tanja S Jørgensen, Marie Skougaard, et al.
Pageof 44

Showing results (241-250 of 435) with videos related to

Sort By:
Pageof 44
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Rheumatology and Therapy|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Rheumatology and Therapy|October 12, 2021
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1Vibeke Strand, Philip J Mease, Enrique R Soriano, et al.
The Journal of Rheumatology|August 4, 2005
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritisJoachim R Kalden, Christian Antoni, Jose M Alvaro-Gracia, et al.
The Journal of Rheumatology|September 3, 2011
Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experienceCharles G Peterfy, Peter Countryman, Annarita Gabriele, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
Rheumatology (Oxford, England)|December 14, 2020
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPYVibeke Strand, Namita Tundia, Alvin Wells, et al.
The Journal of Rheumatology|March 3, 2015
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working GroupDinesh Khanna, Shikha Mittoo, Rohit Aggarwal, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|October 27, 2017
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic StudyChristine Ballegaard, Tanja S Jørgensen, Marie Skougaard, et al.
Pageof 44